ReviewFrontiers in immunology2018
Searching for the Transcriptomic Signature of Immune Tolerance Induction-Biomarkers of Safety and Functionality for Tolerogenic Dendritic Cells and Regulatory Macrophages.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Leveraging current insights on IL-10-producing dendritic cells for developing effective immunotherapeutic approaches.FEBS letters · 2025Review
- Unraveling the Roles of Macrophages in Vascularized Composite Allotransplantation.Biomedicines · 2025Review
- Human tolerogenic dendritic cell subtypes exert divergent effects on induction of cytotoxic CD4Frontiers in immunology · 2025Article
- Identification of novel therapeutic targets and effective anticancer agents for gallbladder cancer by integrating bioinformatics analysis and experimental validation.Frontiers in pharmacology · 2025Article
- Stimulation of regulatory dendritic cells suppresses cytotoxic T cell function and alleviates DEN-induced liver injury, fibrosis and hepatocellular carcinoma.Frontiers in immunology · 2025Article
- Transcriptome profiling of immune rejection mechanisms in a porcine vascularized composite allotransplantation model.Frontiers in immunology · 2024Article
- Tolerogenic dendritic cell reporting: Has a minimum information model made a difference?PeerJ · 2023Article
- In Vitro Generation of Human Tolerogenic Monocyte-Derived Dendritic Cells.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Dendritic cells in liver transplantation immune response.Frontiers in cell and developmental biology · 2023Review
- Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy.Cellular & molecular immunology · 2021Review
- Interleukin 32 Promotes Foxp3Frontiers in cell and developmental biology · 2021Article
- Regulatory Dendritic Cells, T Cell Tolerance, and Dendritic Cell Therapy for Immunologic Disease.Frontiers in immunology · 2021Review
- Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment.Nature communications · 2020Article
- CXCL4 suppresses tolerogenic immune signature of monocyte-derived dendritic cells.European journal of immunology · 2020Article
- Transcriptomics uncovers substantial variability associated with alterations in manufacturing processes of macrophage cell therapy products.Scientific reports · 2020Article
- Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4Frontiers in immunology · 2020Article
- Generation of Powerful Human Tolerogenic Dendritic Cells by Lentiviral-Mediated IL-10 Gene Transfer.Frontiers in immunology · 2020Article
- Current Paradigms of Tolerogenic Dendritic Cells and Clinical Implications for Systemic Lupus Erythematosus.Cells · 2019Review
- Article
- Effect of thermal spring water on human dendritic cell inflammatory response.Journal of inflammation research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The last years have witnessed a breakthrough in the development of cell-based tolerance-inducing cell therapies for the treatment of autoimmune diseases and solid-organ transplantation. Indeed, the use of tolerogenic dendritic cells (tolDC) and regulatory macrophages (Mreg) is currently being tested in Phase I and Phase II clinical trials worldwide, with the aim of finding an effective therapy able to abrogate the inflammatory processes causing these pathologies without compromising the protective immunity of the patients. However, there exists a wide variety of different protocols to generate human tolDC and Mreg and, consequently, the characteristics of each product are heterogeneous. For this reason, the identification of biomarkers able to define their functionality (tolerogenicity) is of great relevance, on the one hand, to guarantee the safety of tolDC and Mreg before administration and, on the other hand, to compare the results between different cell products and laboratories. In this article, we perform an exhaustive review of protocols generating human tolDC and Mreg in the literature, aiming to elucidate if there are any common transcriptomic signature or potential biomarkers of tolerogenicity among the different approaches. However, and although several effectors seem to be induced in common in some of the most reported protocols to generate both tolDC or Mreg, the transcriptomic profile of these cellular products strongly varies depending on the approach used to generate them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.